Sanofi India Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2sapiawydhv6hflml336iyap.pdf

Key Takeaways


Profitability: Efficiency Over Revenue

Vaibhav Karandikar: "In the year-to-date, we have made an improvement in our OpEx base that is close to 10% of the total OpEx base. So we have become more efficient in our expenses to the tune of 10% of our base of expenses, representing something like 50 crores of improvements in efficiencies."

Demerger: Consumer Healthcare Separation

Rodolfo Hrosz: "We continue to be on track with that timeline and expect to be able to execute by May 2024, as it was the case from the beginning of the project."

Growth Pipeline: Launches and Reach

Rodolfo Hrosz: "As you may know, as of today, there is no treatment for this diseases, diabetes type-1. And TZIELD product that belongs to the organisation that we just acquired, is the first treatment for diabetes type-1, and it delays the onset of diabetes type-1, and has already been approved by the FDA, and is already being commercialised in the US."

NLEM Impact: Price Headwinds, Volume Tailwinds


Operating Model: Reorganization and Digital Bets


Guidance & Commitments

CommitmentSpecificsTimeline
Demerger executionNCLT approval and subsequent listing of the separated consumer healthcare entityBy May 2024
Product launchesSanoxaban and Carmada (Dec 2023); Soliqua, Insutage, Cetapine (early 2024); AllegraM, AllegraD (2025 and beyond)H2 2023 through 2025
Partnership decisionCommunicate conclusions from the study on pharma partnerships for brand reach extensionComing months or quarters, if conclusions are positive
Sales force sizeNo significant increase planned; minor adjustments possible with specific launchesOngoing

Key Metrics

MetricQ3 FY23
Revenue growth2% YoY
Domestic sales growthLargely flat YoY
Domestic retained business growth (ex-Soframycin and Lantus impact)~4% YoY
Domestic growth excluding all NLEM impact~5.5% YoY
Profit before tax growth15% YoY
Operating profit growth (year-to-date)16% YoY
Operating profit margin expansion4-5% quarter versus previous year
Blended operating profit margin~30%
Consumer healthcare margin premium over blended~8% to 10% above blended margins
OpEx efficiency savings (year-to-date)~₹50 cr, close to 10% of total OpEx base
Sales force strength1,500 overall, 1,000 for diabetes
Doctor reach expansion (year-to-date)30,000 additional doctors
Demerger expected completionMid-2024, shareholder and creditors meeting scheduled December 18, 2023